Basic outline for phase 2, slide ten. Thoughts? on study having two end points...
Randomized
“HER-Vaxx in combination with standard of care chemotherapy”
OR
“Standard of care chemo: Cisplatin and 5FU or capecitabine or oxaliplatin”
Would of thought the HER-Vaxx would be more beneficial for proof of concept and clinical validation. Which is the more beneficial of the two...?
Ann: Investor Presentation, page-2
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.9¢ |
Change
0.002(5.41%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 4.0¢ | 3.5¢ | $1.163M | 31.27M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2275218 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 196677 | 3 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
